Greenwich LifeSciences, Inc.
GLSI
$8.41
$0.415.13%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 132.16% | 132.03% | 117.99% | 87.79% | 4.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.97% | 72.16% | 74.12% | 71.66% | 14.67% |
| Operating Income | -81.97% | -72.16% | -74.12% | -71.66% | -14.67% |
| Income Before Tax | -85.57% | -76.08% | -79.37% | -77.57% | -17.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -85.57% | -76.08% | -79.37% | -77.57% | -17.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -85.57% | -76.08% | -79.37% | -77.57% | -17.45% |
| EBIT | -81.97% | -72.16% | -74.12% | -71.66% | -14.67% |
| EBITDA | -82.01% | -72.19% | -74.15% | -71.68% | -14.68% |
| EPS Basic | -80.51% | -71.60% | -75.80% | -74.67% | -15.49% |
| Normalized Basic EPS | -80.55% | -71.65% | -75.81% | -74.68% | -15.47% |
| EPS Diluted | -80.51% | -71.60% | -75.80% | -74.67% | -15.49% |
| Normalized Diluted EPS | -80.55% | -71.65% | -75.81% | -74.68% | -15.47% |
| Average Basic Shares Outstanding | 3.04% | 2.66% | 1.88% | 1.29% | 1.49% |
| Average Diluted Shares Outstanding | 3.04% | 2.66% | 1.88% | 1.29% | 1.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |